(VIANEWS) – Alkermes plc (ALKS), Exelixis (EXEL), Quanta Services (PWR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Alkermes plc (ALKS)
73.1% sales growth and 8.72% return on equity
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Alkermes plc has a trailing twelve months EPS of $-0.97.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.72%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Alkermes plc’s EBITDA is 3.04.
Revenue Growth
Year-on-year quarterly revenue growth grew by 123.5%, now sitting on 1.46B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 2100% and 257.1%, respectively.
2. Exelixis (EXEL)
16.2% sales growth and 6.68% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.5.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 42.96. Meaning, the purchaser of the share is investing $42.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.68%.
Volume
Today’s last reported volume for Exelixis is 1911030 which is 23.52% below its average volume of 2498750.
Previous days news about Exelixis(EXEL)
- Exelixis (exel) late-stage study in pancreatic tumors positive. According to Zacks on Friday, 25 August, "Earlier in the week, Exelixis and partner Ipsen announced that the late-stage CONTACT-02 study achieved one of the two primary endpoints in patients with metastatic castration-resistant prostate cancer (mCRPC) who have measurable visceral disease or measurable extrapelvic adenopathy and who have been previously treated with one novel hormonal therapy."
3. Quanta Services (PWR)
15.4% sales growth and 10.93% return on equity
Quanta Services, Inc. provides specialty contracting services in the United States, Canada, Australia, Latin America, and internationally. Its Electric Power Infrastructure Services segment designs, installs, upgrades, repairs, and maintains electric power transmission and distribution infrastructure, and substation facilities, as well as provides other engineering and technical services; designs, installs, maintains, and repairs commercial and industrial wiring; and operates a postsecondary educational institution. It also offers emergency restoration services, including the repair of infrastructure damaged by inclement weather; installation, maintenance, and upgrade of electric power infrastructure; and installation of smart grid technologies on electric power networks. In addition, this segment provides services related to development of solar, wind, and various natural gas generation facilities, as well as related switchyards and transmission infrastructure; and construction of electric power generation facilities. The company's Pipeline and Industrial Infrastructure Services segment designs, installs, repairs, and maintains pipeline transmission and distribution systems, gathering systems, production systems, storage systems, and compressor and pump stations, as well as offers related trenching, directional boring, and mechanized welding services; and designs, installs, and maintains fueling systems, and water and sewer infrastructure. This segment also provides pipeline protection, integrity testing, and rehabilitation and replacement, as well as pipeline support systems, and related structures and facilities fabrication services; and high-pressure and critical-path turnaround, electrical, piping, fabrication, and storage tank services. It serves electric power, energy, and communications companies, as well as commercial, industrial, and governmental entities. The company was founded in 1997 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Quanta Services has a trailing twelve months EPS of $3.34.
PE Ratio
Quanta Services has a trailing twelve months price to earnings ratio of 60.8. Meaning, the purchaser of the share is investing $60.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.93%.
Previous days news about Quanta Services(PWR)
- According to Zacks on Friday, 25 August, "This chart shows the year-to-date performance for the S&P 500 index (red line; +15.2%), homebuilder Lennar (LEN Quick QuoteLEN – Free Report) (green line; up +26.1%), the Zacks Construction sector (blue line; up +27.6%), and Quanta Services (PWR Quick QuotePWR – Free Report) (orange line; up +44.5%)."
4. Alexandria Real Estate Equities (ARE)
11.9% sales growth and 3.4% return on equity
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since its founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science, agtech, and advanced technology campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The trusted partner to approximately 825 tenants, Alexandria has a total market capitalization of $30.6 billion and an asset base in North America of 74.9 million SF as of June 30, 2023, which includes 41.1 million RSF of operating properties and 5.3 million RSF of Class A/A+ properties undergoing construction, 9.4 million RSF of near-term and intermediate-term development and redevelopment projects, and 19.1 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science, agtech, and advanced technology campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation, and technology companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.
Earnings Per Share
As for profitability, Alexandria Real Estate Equities has a trailing twelve months EPS of $3.39.
PE Ratio
Alexandria Real Estate Equities has a trailing twelve months price to earnings ratio of 34.14. Meaning, the purchaser of the share is investing $34.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.4%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 28, 2023, the estimated forward annual dividend rate is 4.96 and the estimated forward annual dividend yield is 4.3%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.9%, now sitting on 2.75B for the twelve trailing months.
Volume
Today’s last reported volume for Alexandria Real Estate Equities is 298799 which is 69.65% below its average volume of 984716.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Alexandria Real Estate Equities’s EBITDA is 11.22.
5. EMCOR Group (EME)
11.7% sales growth and 23.78% return on equity
EMCOR Group, Inc. provides electrical and mechanical construction, and facilities services primarily in the United States and the United Kingdom. It offers design, integration, installation, starts-up, operation, and maintenance services related to electrical power transmission, distribution, and generation systems; energy solutions; premises electrical and lighting systems; process instrumentation in the refining, chemical processing, and food processing industries; low-voltage systems, such as fire alarm, security, and process control systems; voice and data communications systems; roadway and transit lighting, signaling, and fiber optic lines; heating, ventilation, air conditioning, refrigeration, and geothermal solutions; clean-room process ventilation systems; fire protection and suppression systems; plumbing, process, and high-purity piping systems; controls and filtration systems; water and wastewater treatment systems; central plant heating and cooling systems; crane and rigging services; millwright services; and steel fabrication, erection, and welding services. The company also provides building services that cover commercial and government site-based operations and maintenance; facility management, maintenance, and services; outage services to utilities and industrial plants; military base operations support services; mobile mechanical maintenance and services; services for indoor air quality; floor care and janitorial services; landscaping, lot sweeping, and snow removal services; vendor management and call center services; installation and support for building systems; program development, management, and maintenance for energy systems; technical consulting and diagnostic services; infrastructure and building projects; small modification and retrofit projects; and other building services. It offers industrial services to oil, gas, and petrochemical industries. EMCOR Group, Inc. was incorporated in 1987 and is headquartered in Norwalk, Connecticut.
Earnings Per Share
As for profitability, EMCOR Group has a trailing twelve months EPS of $9.02.
PE Ratio
EMCOR Group has a trailing twelve months price to earnings ratio of 24.05. Meaning, the purchaser of the share is investing $24.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.78%.
Sales Growth
EMCOR Group’s sales growth is 11.8% for the current quarter and 11.7% for the next.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jul 18, 2023, the estimated forward annual dividend rate is 0.72 and the estimated forward annual dividend yield is 0.32%.
Yearly Top and Bottom Value
EMCOR Group’s stock is valued at $216.93 at 01:22 EST, below its 52-week high of $223.49 and way higher than its 52-week low of $112.85.
6. Progress Software Corporation (PRGS)
10.7% sales growth and 20.55% return on equity
Progress Software Corporation develops, deploys, and manages business applications. The company offers OpenEdge, a development software, which builds multi-language applications for secure deployment across various platforms and devices, as well as cloud; developer tools that consists of components for user interface development for Web, mobile, desktop, chat, and AR/VR apps, as well as automated application testing and reporting tools; Sitefinity, a web content management and customer analytics platform; Corticon, a business rules management system that provides applications with decision automation and change process, and decision-related insight capabilities. It also offers DataDirect Connect, which provides data connectivity using industry-standard interfaces to connect applications running on various platforms; MOVEit that offers secure collaboration and automated file transfers of critical business information; Chef, an infrastructure automation platform to build, deploy, manage, and secure applications in multi-cloud and hybrid environments, and on-premises; and WhatsUp Gold, a network monitoring solution. In addition, the company provides Kemp LoadMaster, a load balancing solutions; and Kemp Flowmon network performance monitoring and diagnostic solutions that collect and analyze network telemetry from various sources. Further, it provides project management, implementation, custom development, programming, and other services, as well as web-enable applications; and training services. The company sells its products to end users, independent software vendors, original equipment manufacturers, and system integrators. It has operations in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. The company was founded in 1981 and is headquartered in Burlington, Massachusetts.
Earnings Per Share
As for profitability, Progress Software Corporation has a trailing twelve months EPS of $1.85.
PE Ratio
Progress Software Corporation has a trailing twelve months price to earnings ratio of 33.15. Meaning, the purchaser of the share is investing $33.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.55%.
Moving Average
Progress Software Corporation’s worth is above its 50-day moving average of $58.51 and above its 200-day moving average of $55.92.
7. Ambev (ABEV)
7.1% sales growth and 16.92% return on equity
Ambev S.A., through its subsidiaries, engages in the production, distribution, and sale of beer, draft beer, carbonated soft drinks, other non-alcoholic beverages, malt, and food products. It offers beer primarily under the Skol, Brahma, Antarctica, Brahva, Budweiser, Bud Light, Beck, Leffe and Hoegaarden, Bucanero, Cristal, Mayabe, Presidente, Presidente Light, Brahma Light, Bohemia, The One, Corona, Modelo Especial, Stella Artois, Quilmes Clásica, Paceña, Taquiña, Huari, Becker, Cusqueña, Michelob Ultra, Busch, Pilsen, Ouro Fino, Banks, Deputy, Patricia, Labatt Blue, Alexander Keith's, and Kokanee brands. The company also provides carbonated soft drinks, bottled water, isotonic beverages, energy drinks, coconut water, powdered and natural juices, and ready-to-drink teas under the Guaraná Antarctica, Gatorade, H2OH!, Lipton Iced Tea, Fusion, Do Bem, Pepsi-Cola, Canada Dry, Squirt, Red Rock, Red Bull, Seven Up, Nutrl, Bud Light Seltzer, Palm Bay, and Mike's brands. It offers its products through a network of third-party distributors and a direct distribution system. The company was founded in 1885 and is headquartered in São Paulo, Brazil. Ambev S.A. operates as a subsidiary of Interbrew International B.V.
Earnings Per Share
As for profitability, Ambev has a trailing twelve months EPS of $0.18.
PE Ratio
Ambev has a trailing twelve months price to earnings ratio of 15.75. Meaning, the purchaser of the share is investing $15.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.92%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Dec 19, 2022, the estimated forward annual dividend rate is 0.14 and the estimated forward annual dividend yield is 5.05%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.1%, now sitting on 82.71B for the twelve trailing months.
